Hereditary thrombophilia

Thrombosis Journal

Volumn 4, Issue , 2006, Pages

  Khan, Salwa ^a   Dickerman, Joseph D ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN C; PROTEIN S; PROTHROMBIN; PYRIDOXINE; THROMBIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; UROKINASE;

ACTIVATED PROTEIN C RESISTANCE; AMINO ACID SUBSTITUTION; ANTITHROMBIN DEFICIENCY; ARTERY THROMBOSIS; AUTOSOMAL DOMINANT INHERITANCE; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; DYSFIBRINOGENEMIA; ENZYME INACTIVATION; FIBRINOLYSIS; GENE MUTATION; HEREDITY; HETEROZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; LUNG EMBOLISM; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN C DEFICIENCY; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION;

EID: 33749589960     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-4-15     Document Type: Review

References (109)

1. Hoppe C, Matsunaga A. Pediatric Thrombosis. Pediatric Clin of North America 2002, 49:1257-1283.
2. Rosendaal FR: Venous Thrombosis, a multicausal disease. Lancet 1999, 353:1167-73.
3. Lane DA, Mannucci PM, Bauer KA, et al.: Inherited thrombophilia: part I. Thromb Haemost 1996, 76:651.
4. Esmon CT, Protein C. The regulacion of natural anticoagulant pathways. Science 1987, 235:1348.
5. Heijboer H, Brandjes DP, Buller HR, Sturk A, ten Cate JW: Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 323(22): 1512-6. 1990 Nov 29
6. Lane DA, Mannucci PM, Bauer KA, et al.: Inherited thrombophilia: part 2. Thromb Hoemost 1996, 76:824.
7. Egeberg O: Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965, 13:576-300.
8. Griffin JH, Evatt B, Zimmerman TS, et al.: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981, 68: 1370-1373.
9. Comp PC, Nixon RR, Cooper MR, Esmon CT: Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest 1984, 74(6):2082-8.
10. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993, 90:1004-1008.
11. Bertina RM, Koeleman BPC, Koster T, et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994, 369:64-66.
12. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR: Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152-5. 1995 Jan 21
13. Feero WG: Genetic Thrombophilia. Primary Care 2004, 31(3): 685-709.
14. Chalmers EA: Heritable thrombophilia and childhood thrombosis. Blood Rev 2001, 15(4):181-9.
15. Press RD, Bauer KA, Kujovich JL, Heit JA: Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002, 126(II):1304-18.
16. Brenner BR, Nowak-Gottl U, Kosch A, Manco-Johnson M, Laposata M: Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med 2002, 126(11):1296-303.
17. Koeleman BP, Reitsma PH, Bertina RM: Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997, 34(3):256-64.
18. Kalafatis M, Bertina RM, Rand MD, Mann KG: Characterization of the molecular defect in factor VR506Q. J Biol Chem 270(8): 4053-7. 1995 Feb 24
19. Shen L, Dahlback B: Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor Villa. J Biol Chem 269(29):18735-8. 1994 Jul 22
20. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342(8886-8887):1503-6. 1993 Dec 18-25
21. Williamson D, Brown K, Luddington R, Baglin C, Baglin T: Factor V Cambridge: a new mutation (Arg306 - Thr) associated with resistance to activated protein C. Blood 91(4):1140-4.1998 Feb 15
22. Chan WP, Lee CK, Kwong YL, Lam CK, Liang R: A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 91 (4): 1135-9. 1998 Feb 15
23. Guasch JF, Lensen RP, Bertina RM: Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance. Thromb Haemost 1997, 77(2):252-7.
24. Ridker PM, Miletich JP, Hennekens CH, Buring JE: Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277(16): 1305-7. 1997 Apr 23-30
25. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE, Hill JA: Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 128(12 Pt 1):1000-3. 1998 Jun 15
26. Martinelli I, Mannucci PM, De Stefano V, Taioli E, Rossi V, Crosti F, Paciaroni K, Leone G: Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 92(7):2353-8. 1998 Oct 1
27. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 346(8983):1133-4. 1995 Oct 28
28. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88(10):3698-703. 1996 Nov 15
29. Soria JM, Almasy L, Souto JC, Tirado I, Borell M, Mateo J, Slifer S, Stone W, Blangero J: Linkage analysis demonstrates that the prothrombin G20210A mutation jointly influences plasma prothrombin levels and risk of thrombosis. Blood 95(9): 2780-5. 2000 May 1
30. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D: Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998, 80 (1):49-51.
31. Zivelin A, Rosenberg N, Faier S, Kornbrot N, Peretz H, Mannhalter C, Horellou MH, Seligsohn U: A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood 92(4):11 19-24. 1998 Aug 15
32. Foster DC, Yoshitake S, Davie EW: The nucleotide sequence of the gene for human protein C. Proc Natl Acad Sci, 1985, 82(14): 4673-7.
33. Clouse LH, Comp PC: The regulation of hemostasis: The protein C system. N Engl J Med 1986, 314:1298.
34. Reitsma PH, Bernardi F, Doig RG, et al.: Protein C deficiency: A database of mutations, 1995 update. Thromb Haemost 1995, 73:876.
35. Broekmans AW, Bertina RM, Protein C: In: Recent Advances in Blood Coagulation. Volume 4. Edited by: Poller L. Churchill Livingstone New York; 1985:117.
36. Manco-Johnson MJ, Marlar RA, Jacobson LJ, Hays T, Warady BA: Severe protein C deficiency in newborn infants. J Pediatr 1988, 113(2):359-63.
37. Chan YC, Valenti D, Mansfield AO, Stansby G: Warfarin induced skin necrosis. Br J Surg 2000, 87(3):266-72.
38. Greer IA: Inherited thrombophilia and venous thromboembolism. Best Pract Res Clin Obstet Gynaecol 2003, 17(3):413-25.
39. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B: The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989, 73(3):712-7.
40. Lensen RP, Rosendaal FR, Koster T, Allaart CF, de Ronde H, Vandenbroucke JP, Reitsma PH, Bertina RM: Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 88(11):4205-8. 1996 Dec 1
41. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW: Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994, 87(1):106-12.
42. Koster T, Rosendaal FR, Briet E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP: Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 85(10):2756-61. 1995 May 15
43. Broekmans AW, Veltkamp JJ, Bertina RM: Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 309(6):340-4. 1983 Aug 11
44. Schmidel DK, Tatro AV, Phelps LG, Tomczak JA, Long GL: Organization of the human protein S genes. Biochemistry 29(34): 7845-52. 1990 Aug 28
45. Gandrille S, Borgel D, Sala N, et al.: Protein S deficiency: a database of mutations - summary of the first update. Thromb Haemost 2000, 84:918.
46. Simmonds RE, Ireland H, Kunz G, Lane DA: Identification of 19 protein S gene mutations in patients with phenotypic protein S deficiency and thrombosis. Protein S Study Group. Blood 88(11):4195-204. 1996 Dec 1
47. Gandrille S, Borgel D, Eschwege-Gufflet V, Aillaud M, Dreyfus M, Matheron C, Gaussem P, Abgrall JF, Jude B, Sie P, et al.: Identification of 15 different candidate causal point mutations and three polymorphisms in 19 patients with protein S deficiency using a scanning method for the analysis of the protein S active gene. Blood 85(1):130-8. 1995 Jan 1
48. Zoller B, Svensson PJ, He X, Dahlback B: Identification of the same factor V mutation in 47 out of 60 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994, 94:2521-4.
49. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC: A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol 2001, 113(3):636-41.
50. Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J: Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997, 77(3):444-51.
51. Engesser L, Broekmans AW, Briet E, Brommer EJ, Bertina RM: Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987, 106(5):677-82.
52. Simmonds RE, Ireland H, Lane DA, Zoller B, Garcia de Frutos; P, Dahlback B: Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 128(1):8-14. 1998 Jan 1
53. Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK, Bayliss P, Peake IR, Miller GJ, Preston FE: Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 95(6): 1935-41. 2000 Mar 15
54. Mahasandana C, Veerakul G, Tanphaichitr VS, Suvatte V, Opartkiattikul N, Hathaway WE: Homozygous protein S deficiency: 7-year follow-up. Thromb Haemost 1996, 76(6):1122.
55. Ambruso DR, Leonard BD, Bies RD, Jacobson L, Hathaway WE, Reeve EB: Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 1982, 60(1):78-83.
56. Lane DA, Bayston T, Olds RJ, et al.: Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 1997, 77:197.
57. Thaler E, Lechner K: Antithrombin III deficiency and thromboembolism. In Clinics in Haematology Volume 10. Edited by: Prentice CRM. Saunders London; 1981:369.
58. Hoffman: Hematology: Basic Principles and Practice. Churchill Livingstone Inc 3 2000.
59. Picard V, Dautzenberg MD, Villoutreix BO, Orliaguet G, Alhenc-Gelas M, Aiach M: Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 102(3):919-25. 2003 Aug 1
60. Kuhle S, Lane DA, Jochmanns K, Male C, Quehenberger P, Lechner K, Pabinger I: Homozygous antithrombin deficiency type 11 (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 2001, 86(4):1007-11.
61. Lijnen HR, Soria J, Soria C, et al.: Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 1984, 51: 108.
62. Hanss M, Biot F: A Database For Human Fibrinogen Variants. Ann N Y Acad Sci 2001, 936:89-90 [http://www.geht.org/databaseang/fibrinogen].
63. Haverkate F, Samama M: Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995, 73(1):151-61.
64. Duga S, Asselta R, Santagostino E, Zeinali S, Simonic T, Malcovati M, Mannucci PM, Tenchini ML: Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. Blood 95(4):1336-41. 2000 Feb 15
65. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N: Thermolabile methylenetetrahydrafolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991, 48(3):536-45.
66. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers CJ, den Heijer M, Kluijtmans LA, van den Heuvel LP: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 1995, 10(1):111-3.
67. McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969. 56:111-128. [Medline]
68. McCully KS: Homocysteine and vascular disease. Nat Med 1996, 2:386-389. [Medline]
69. D'Angelo A, Selhub J: Homocysteine and thrombotic disease. Blood 1997, 90:1.
70. den Heijer M, Kostor T, Blom HJ, et al.: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996, 334:759-762. [Abstract/Full Text]
71. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ: Interrelation of hyperhomocysteinemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997, 95:1777-1782.
72. Bønaa KH: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354(15): 1578-88. 13-APR-2006
73. Loscalzo J: Homocysteine trials - clear outcomes for complex reasons. N Engl Med 354(15):1629-32. 13-APR-2006
74. De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G: Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000, 26(3):305-11.
75. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 342(8879):1076-9. 1993 Oct 30
76. O'Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M: High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997, 77(5):825-8.
77. Kraaijenhagen RA, in't Anker PS, Koopman MM, Reitsma PH, Prins MH, van den Ende A, Buller HR: High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000, 83(1):5-9.
78. Legnani C, Cosmi B, Cini M, Frascaro M, Guazzaloca G, Palareti G: High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. British Journal of Haemotology 2004, 124(5):504.
79. Boland EJ, Liu YC, Walter CA, Herbert DC, Weaker FJ, Odom MW, Jagadeeswaran P: Age-specific regulation of clotting factor IX gene expression in normal and transgenic mice. Blood 1995, 86(6):2198-205. 1995 Sep 15
80. van Hylckama VA, et al.: High levels of factor IX increase the risk of venous thrombosis. Blood 2000, 95:3678-82.
81. Meijers JCM, Tekelenburg WLH, Bouma BN, Rogier BM, Rosendaal FR: High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000, 342:696-701.
82. Lammle B, Wuillemin WA, Huber I, et al.: Thromboembolism and bleeding tendency in congenital factor XII deficiency - a study on 74 subjects from 14 Swiss families. Thromb Haemost 1991, 65:117.
83. Girolami A, Randi ML, Gavasso S, Lombardi AM, Spiezia F: The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors. J Thromb Thrombolysis 2004, 17(2):139-43.
84. Marcucci R, Liotta AA, Cellai AP, Rogolino A, Gori AM, Giusti B, Poli D, Fedi S, Abbate R, Prisco D: Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism. Am J Med 115(8):601-5. 2003 Dec 1
85. Caplice NM, Panetta C, Peterson TE, Kleppe LS: Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: a novel link between lipoproteins and thrombosis. Blood 2001, 98: 2980.
86. von Depka M, Nowak-Gottl U, Eisert R, Dieterich C, Barthels M, Scharrer I, Ganser A, Ehrenforth S: Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96(10):3364-8.2000 Nov 15
87. Nowak-Gottl U, Junker R, Hartmeier M, Koch HG, Munchow N, Assmann G, von Eckardstein A: Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation 100(7):743-8. 1999 Aug 17
88. Reiner Alexander P, Siscovick David S, Rosendaal Frits R: Platelet glycoprotein gene polymorphisms and risk of thrombosis. facts and fancies. Reviews In Clinical & Experimental Hematology 2001, 5(3):262-287.
89. Kunicki TI: The influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002, 22(1):14-20.
90. Brandt JT: Plasminogen and Tissue-Type Plasminogen Activator Deficiency as Risk Factors for Thromboembolic Disease. Archives of Pathology and Laboratory Medicine 2002, 126(11): 1376-1381.
91. Aoki N, Moroi M, Sakata Y, et al.: Abnormal plasminogen. A hereditary abnormality found in a patient with recurrent thrombosis. J Clin Invest 1978, 61:1186.
92. Demarmels Biasiutti F, Sulzer I, Stucki B, Wuillemin WA, Furlan M, Lammle B: Is plasminogen deficiency a thrombotic risk factor? a study on 23 thrombophilic patients and their family members. Thromb Haemost 1998, 80:167-170.
93. Schott D, Dempfle CE, Beck P, et al.: Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. N Engl J Med 1998, 339:1679.
94. Schulman S, Wiman B: The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Duration of Anticoagulation (DURAC) Trial Study Group. Thromb Haemost 1996, 75(4):607-11.
95. Francis C: Plasminogen Activator Inhibitor-1 Levels and Polymorphisms: Association With Venous Thromboembolism. Archives of Pathology and Laboratory Medicine 2002, 126(11): 1401-1404.
96. Crowther MA, Roberts J, Roberts R, et al.: Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost 2001, 85:390-394.
97. Esmon CT, Esmon NL, Harris KW: Complex formation between thrombin and thrombomodulin inhibits both thrombin-catalyzed fibrin formation and factor V activation. J Biol Chem 257 (14):7944-7. 1982 Jul 25
98. Ohlin AK, Marlar RA. The first mutation identified in the thrombomodulin gene in a 45-year-old man presenting with thromboembolic disease. Blood 85(2):330-6. 1995 Jan 15
99. Ohlin AK, Norlund L, Marlar RA: Thrombomodulin gene variations and thromboembolic disease. Thromb Haemost 1997, 78(1):396-400.
100. Bertina RM, van der Linden IK, Engesser L, Muller HP, Brommer EJ: Hereditary heparin cofactor II deficiency and the risk of development of thrombosis. Thromb Haemost 57(2):196-200. 1987 Apr 7
101. Villa P, Aznar J, Vaya A, Espana F, Ferrando F, Mira Y, Estelles A: Hereditary homozygous heparin cofactor II deficiency and the risk of developing venous thrombosis. Thromb Haemost 1999, 82(3):1011-4.
102. Lijnen HR, Holylaerts M, Collen D: Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983, 258: 3803.
103. Shigekiyo T, Ohshima T, Oka H, Tomonari A, Azuma H, Saito S: Congenital histidine-rich glycoprotein deficiency. Thromb Haemost 70(2):263-5. 1993 Aug 2
104. Mustafa S, Mannhalter C, Rintelen C, Kyrle PA, Knobl P, Lechner K, Pabinger I: Clinical features of thrombophilia in families with gene defects in protein C or protein S combined with factor V Leiden. Blood Coagul Fibrinolysis 1998, 9(1):85-9.
105. Koeleman BP, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM: Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995, 74(2):580-3.
106. Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA: Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996, 75(3):417-21.
107. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, Berliner S, Inbal A, Many A, Lubetsky A, Varon D, Martinowitz U, Seligsohn S: Single and Combined Prothrombotic Factors in Patients with Idiopathic Venous Thromboembolism. Arterioscler Thromb Vasc Biol 1999, 19:511-518.
108. Emmerich J, Rosendaal FR, Cattaneo, M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL: Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost 2001, 86(3):809-16.
109. Gallus AS: Management options for thrombophilias. Seminal Thromb Hemostasis 2005, 31(1):118-26.